Introduction to 21 CFR 312.57
The Code of Federal Regulations, specifically 21 CFR 312.57, outlines the requirements for recordkeeping and retention in Investigational New Drug (IND) studies. This regulation is crucial for ensuring the integrity and validity of clinical trials, as well as compliance with FDA regulations.
By adhering to these guidelines, sponsors and researchers can maintain accurate and comprehensive records, facilitating the review and approval process for new drugs and treatments. This, in turn, contributes to public health and safety by ensuring that only safe and effective medications are brought to market.
Recordkeeping Requirements
21 CFR 312.57 mandates that sponsors and investigators maintain detailed records of all aspects of the IND study, including protocol development, subject enrollment, and data collection. These records must be accurate, complete, and legible, and must be retained for a specified period.
The regulation also requires that records be stored in a secure and accessible manner, with adequate provisions for backup and retrieval. This ensures that critical information can be readily retrieved and reviewed, both during the study and in the event of an audit or inspection.
Retention of Records
The retention of records is a critical component of 21 CFR 312.57, as it ensures that documentation is available for review and inspection for a specified period. The regulation requires that records be retained for at least two years following the date of the last approval of the marketing application, or, if an application is not approved, until two years after the investigation is discontinued.
This retention period allows for the verification of data and the validation of study results, as well as the identification of any potential issues or discrepancies. By maintaining accurate and complete records, sponsors and researchers can demonstrate compliance with regulatory requirements and ensure the integrity of the study.
Electronic Recordkeeping
The use of electronic recordkeeping systems has become increasingly prevalent in clinical trials, and 21 CFR 312.57 provides guidance on the requirements for electronic records. The regulation stipulates that electronic records must be maintained in a secure and accessible manner, with adequate provisions for backup and retrieval.
Electronic recordkeeping systems must also be validated to ensure that they are reliable and compliant with regulatory requirements. This includes ensuring that the system is secure, with adequate controls to prevent unauthorized access or modification of data, and that it is capable of generating accurate and complete records.
Compliance and Inspection
Compliance with 21 CFR 312.57 is essential to ensure the integrity and validity of IND studies. Sponsors and researchers must be prepared for inspections and audits, which may be conducted by the FDA or other regulatory agencies.
During an inspection or audit, the regulatory agency will review records and documentation to verify compliance with the regulation. It is essential that sponsors and researchers are able to demonstrate compliance with the requirements for recordkeeping and retention, as non-compliance can result in significant consequences, including delays or termination of the study.
Frequently Asked Questions
What is the purpose of 21 CFR 312.57?
The purpose of 21 CFR 312.57 is to outline the requirements for recordkeeping and retention in IND studies, ensuring the integrity and validity of clinical trials and compliance with FDA regulations.
What types of records must be maintained under 21 CFR 312.57?
The regulation requires that sponsors and investigators maintain detailed records of all aspects of the IND study, including protocol development, subject enrollment, and data collection.
How long must records be retained under 21 CFR 312.57?
Records must be retained for at least two years following the date of the last approval of the marketing application, or, if an application is not approved, until two years after the investigation is discontinued.
Can electronic recordkeeping systems be used under 21 CFR 312.57?
Yes, electronic recordkeeping systems can be used, but they must be validated to ensure that they are reliable and compliant with regulatory requirements.
What are the consequences of non-compliance with 21 CFR 312.57?
Non-compliance can result in significant consequences, including delays or termination of the study, as well as regulatory action by the FDA or other agencies.
How can sponsors and researchers ensure compliance with 21 CFR 312.57?
Sponsors and researchers can ensure compliance by maintaining accurate and complete records, storing them in a secure and accessible manner, and being prepared for inspections and audits.